<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Antithrombin III is an important element of the endogenous <z:mp ids='MP_0005048'>thrombosis</z:mp> protection system </plain></SENT>
<SENT sid="1" pm="."><plain>Congenital <z:hpo ids='HP_0001976'>Anti-thrombin III deficiencies</z:hpo> are associated with increased incidence of thrombo-embolisms </plain></SENT>
<SENT sid="2" pm="."><plain>If Antithrombin III is determined at the time of operation, postoperative deficiencies resulting from an increased turnover rate can be identified </plain></SENT>
<SENT sid="3" pm="."><plain>Determination of Antithrombin III is not suitable for prognosticating the occurrence of thrombo-embolic complications in <z:hpo ids='HP_0003745'>isolated cases</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>Antithrombin III can be administered in the form of fresh frozen plasma (FFP), though it is also available as Antithrombin III concentrate </plain></SENT>
<SENT sid="5" pm="."><plain>So far no investigations have been carried out to establish whether it is possible to improve <z:mp ids='MP_0005048'>thrombosis</z:mp> protection with or without <z:chebi fb="5" ids="28304">heparin</z:chebi> prophylaxis by concentrated Antithrombin III substitution </plain></SENT>
</text></document>